Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AX-TCRT-001
- Development stage
- Unknown
- Lead developer
- Axe-Bio
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AX-TCRT-001 is an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) antigen. Developed by Axe-Bio, the therapy involves the genetic modification of a patient's own T cells to express a high-affinity TCR specific for NY-ESO-1 peptides presented in the context of HLA-A*02:01. NY-ESO-1 is a cancer-testis antigen frequently overexpressed in various solid tumors, including synovial sarcoma, myxoid/round cell liposarcoma, and melanoma, while having limited expression in normal tissues. By redirecting T cells to recognize and eliminate NY-ESO-1-positive cancer cells, AX-TCRT-001 aims to provide a potent and specific anti-tumor response. The therapy is currently being evaluated in clinical trials for patients with NY-ESO-1 positive advanced solid tumors.
- Other names
- NY-ESO-1 TCR-TNY-ESO1 TCR-TNY-ESO 1 TCR-T
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on AX-TCRT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AX-TCRT-001.